Ensysce Biosciences (ENSC) Cash & Equivalents (2017 - 2025)
Ensysce Biosciences' Cash & Equivalents came in at $4.31 million for Q4 2025, up 23.1% from $3.5 million a year earlier and up 157.6% from the prior quarter.
Powered by 
Analysis
Ensysce Biosciences (ENSC) Cash & Equivalents (2017 - 2025) Analysis & Trends
Going back to Q4 2017, Ensysce Biosciences' Cash & Equivalents data covers 33 quarters.
- Cash & Equivalents carries a five-year compound annual growth rate of 85.9% (FY2020 to FY2025).
- Going back by year, Cash & Equivalents was $3.5 million in FY2024 (+211.7%), $1.12 million in FY2023 (-64.3%), $3.15 million in FY2022 (-74.3%) and $12.26 million in FY2021.
- The Q4 2025 figure represents the highest quarterly Cash & Equivalents since Q3 2022.
- Year-over-year, Cash & Equivalents increased in five of the last eight quarters, with growth averaging 66.0%.
- The fastest year-over-year change in Cash & Equivalents over five years came in Q4 2024 (growth of 211.7%), and the weakest in Q1 2021 (a decline of 89.3%).
- Business Quant data shows ENSC's Cash & Equivalents at $1.67 million (Q3 2025), $2.21 million (Q2 2025) and $3.05 million (Q1 2025) in the three quarters before Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,144.36 Bn | 1,112.95 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 635.36 Bn | 555.22 Bn | 17.30 Bn | 16.91 Bn |
| 3 | AbbVie | 502.79 Bn | 475.90 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 356.08 Bn | 310.46 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 300.87 Bn | 264.86 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 264.31 Bn | 237.99 Bn | 12.86 Bn | 4.90 Bn |
| 7 | Amgen | 239.07 Bn | 194.47 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 194.50 Bn | 168.70 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 171.00 Bn | 117.64 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Ensysce Biosciences | 1.25 Mn | -9.99 Mn | - | 4.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 4.31 Mn |
| Sep 30, 2025 | 1.67 Mn |
| Jun 30, 2025 | 2.21 Mn |
| Mar 31, 2025 | 3.05 Mn |
| Dec 31, 2024 | 3.50 Mn |
| Sep 30, 2024 | 4.15 Mn |
| Jun 30, 2024 | 1.04 Mn |
| Mar 31, 2024 | 3.40 Mn |
| Dec 31, 2023 | 1.12 Mn |
| Sep 30, 2023 | 1.46 Mn |
| Jun 30, 2023 | 3.83 Mn |
| Mar 31, 2023 | 1.42 Mn |
| Dec 31, 2022 | 3.15 Mn |
| Sep 30, 2022 | 4.50 Mn |
| Jun 30, 2022 | 3.73 Mn |
| Mar 31, 2022 | 8.44 Mn |
| Dec 31, 2021 | 12.26 Mn |
| Sep 30, 2021 | 6.85 Mn |
| Jun 30, 2021 | 8.01 Mn |
| Mar 31, 2021 | 18,034.00 |
API Access
Ensysce Biosciences Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=ENSC&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "ENSC", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=ENSC&period=max&api_key=YOUR_API_KEY");
const data = await res.json();